Pharmacogenomics in depression and antidepressants
Genetic factors are believe y a major role in the variation of treatment response and the incidence of adverse effects to medication. The aim of pharmacogenetics is to elucidate this variability according to hereditary differences. Considering current hypotheses for the mechanisms of action of antid...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Les Laboratoires Servier
2005
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181738/ |
| id |
pubmed-3181738 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-31817382011-10-27 Pharmacogenomics in depression and antidepressants Bondy, Brigitta Pharmacological Aspects Genetic factors are believe y a major role in the variation of treatment response and the incidence of adverse effects to medication. The aim of pharmacogenetics is to elucidate this variability according to hereditary differences. Considering current hypotheses for the mechanisms of action of antidepressants, most investigations to date have concentrated on mutations in genes coding either for the pathways in the serotonergic and noradrenergic systems or for drug-metabolizing enzymes. Recent studies shifted the emphasis on the mains mechanism of drug action from changes in neurotransmitter concentration or receptor function toward long-lasting adaptive processes within the neurons. Although the results are controversial, many studies support the hypothesis that psychopharmacogenetics will help predict an individual's drug response, while minimizing the side effects. The inclusion of functional genomics, investigate the complex gene and/or protein expression in response to a given drug, may lead to the development of novel and safer drugs. Les Laboratoires Servier 2005-09 /pmc/articles/PMC3181738/ /pubmed/16156381 Text en Copyright: © 2005 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Bondy, Brigitta |
| spellingShingle |
Bondy, Brigitta Pharmacogenomics in depression and antidepressants |
| author_facet |
Bondy, Brigitta |
| author_sort |
Bondy, Brigitta |
| title |
Pharmacogenomics in depression and antidepressants |
| title_short |
Pharmacogenomics in depression and antidepressants |
| title_full |
Pharmacogenomics in depression and antidepressants |
| title_fullStr |
Pharmacogenomics in depression and antidepressants |
| title_full_unstemmed |
Pharmacogenomics in depression and antidepressants |
| title_sort |
pharmacogenomics in depression and antidepressants |
| description |
Genetic factors are believe y a major role in the variation of treatment response and the incidence of adverse effects to medication. The aim of pharmacogenetics is to elucidate this variability according to hereditary differences. Considering current hypotheses for the mechanisms of action of antidepressants, most investigations to date have concentrated on mutations in genes coding either for the pathways in the serotonergic and noradrenergic systems or for drug-metabolizing enzymes. Recent studies shifted the emphasis on the mains mechanism of drug action from changes in neurotransmitter concentration or receptor function toward long-lasting adaptive processes within the neurons. Although the results are controversial, many studies support the hypothesis that psychopharmacogenetics will help predict an individual's drug response, while minimizing the side effects. The inclusion of functional genomics, investigate the complex gene and/or protein expression in response to a given drug, may lead to the development of novel and safer drugs. |
| publisher |
Les Laboratoires Servier |
| publishDate |
2005 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181738/ |
| _version_ |
1611477905021337600 |